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Accepted 4 May 2016; Published online 2 June 2016AbstractObjective: Validation of clinical prediction models traditionally refers to the assessment of model performance in new patients. We
studied different approaches to geographic and temporal validation in the setting of multicenter data from two time periods.
Study Design and Setting: We illustrated different analytic methods for validation using a sample of 14,857 patients hospitalized with
heart failure at 90 hospitals in two distinct time periods. Bootstrap resampling was used to assess internal validity.Meta-analytic methods were
used to assess geographic transportability. Each hospital was used once as a validation sample, with the remaining hospitals used for model
derivation. Hospital-specific estimates of discrimination (c-statistic) and calibration (calibration intercepts and slopes) were pooled using
random-effects meta-analysis methods. I2 statistics and prediction interval width quantified geographic transportability. Temporal transport-
ability was assessed using patients from the earlier period for model derivation and patients from the later period for model validation.
Results: Estimates of reproducibility, pooled hospital-specific performance, and temporal transportability were on average very similar,
with c-statistics of 0.75. Between-hospital variation was moderate according to I2 statistics and prediction intervals for c-statistics.
Conclusion: This study illustrates how performance of prediction models can be assessed in settings with multicenter data at different
time periods.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Key findings
 Using data on patients hospitalized with heart fail-
ure in the Canadian province of Ontario and a pre-
viously derived clinical prediction model, we
found that several strategies to quantify model per-
formance showed similar overall results, with mod-
erate variation in center-specific performance.
 Ninety-five percent prediction intervals for a new
hospital-specific c-statistic were moderately wide
in each of the two time periods.
What this adds to what was known?
 Bootstrap correction for optimism resulted in a
similar overall estimate of model performance as
a leave-one-hospital-out approach, in which each
hospital was used once for model validation.
 Random-effects meta-analysis provided insight
into the variability of center-specific performance
measures as an indication of geographical trans-
portability of a prediction model, when the focus
is on within-center performance of the model.
What is the implication and what should change
now?
 Appropriate statistical methods should be used to
quantify the geographic and temporal portability
of clinical prediction models.
 Validation studies of clinical prediction models
should carefully describe whether overall validity
of a model is reported, or that transportability is
addressed by assessment of geographical or tempo-
ral variability in performance.
P.C. Austin et al. / Journal of Clwas developed. Validation is an important issue in the sci-
entific development of prediction models toward wide
application.
Different frameworks for model validation have been
proposed. Internal validation is commonly differentiated
from external and temporal validation [1,2]. Interval valida-
tion, also referred to as reproducibility [3,4], describes how
well the model performs in patients who were not included
in model development, but who are from the same underly-
ing population. Temporal validation refers to the perfor-
mance of the model on subsequent patients in settings
similar to that in which the model was developed. External
validation refers to the process of examining the perfor-
mance of the model on data from centers different from
those which participated in model development. The term
transportability refers to a model that maintains itsperformance in a population that is different from that in
which it was developed [3,4]. Different aspects of trans-
portability have been defined: historical, geographic, meth-
odologic (model performs well when data were collected
using different methods), spectrum (model performs well
when the distribution of disease severity differs), and
follow-up interval (model performs well when the outcome
is assessed over a different duration of follow-up time) [3].
We aimed to describe and illustrate methods for assess-
ing the geographic and temporal transportability of clinical
prediction models. Accordingly, we analyzed data on pa-
tients hospitalized with congestive heart failure (CHF) at
a large number of hospitals in two distinct time periods.2. Methods
2.1. Data sources
The study used patients from The Enhanced Feedback
for Effective Cardiac Treatment (EFFECT) Study, which
was an initiative to improve the quality of care for patients
with cardiovascular disease in Ontario [5]. Only patients
admitted to those 90 hospitals that participated in both
phases of the study were included in the current study.
The present study included 7,549 patients hospitalized with
CHF during the first phase of the study (April 1999 to
March 2001) and 7,308 patients hospitalized during the sec-
ond phase of the study (April 2004 to March 2005).
There was a notable difference in the inclusion and
exclusion criteria between the two phases of the study. Pa-
tients were excluded from the first phase if they had had a
prior hospitalization for CHF. This exclusion criterion was
removed from the second phase of the study. This enabled
us to examine both temporal portability and spectrum or
methodological portability.
2.2. Heart failure mortality prediction model
The EFFECT-HF mortality prediction models estimate
the probability of death within 30 days and 1 year of hospi-
talization for CHF [6]. The model for predicting 1-year mor-
tality uses 11 variables: age, systolic blood pressure on
admission, respiratory rate on admission, low sodium serum
concentration (!136 mEq/L), low serum hemoglobin (!
10.0 g/dL), serum urea nitrogen, presence of cerebrovascular
disease, presence of dementia, chronic obstructive pulmo-
nary disease, hepatic cirrhosis, and cancer.
2.3. Measures of model performance
Discrimination is a key component of assessing the val-
idity of a clinical prediction model. We quantified discrim-
ination using the c-statistic [7,8]. We used two methods for
assessing model calibration. First, loess smoothers were
used to describe graphically the agreement between pre-
dicted probabilities and the observed probabilities of the
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intercepts and slopes as summary measures [10]. The cali-
bration intercept, also known as calibration in the large, is
equal to the intercept of a logistic regression model in
which the binary outcome is regressed on the estimated
linear predictor when the slope is fixed at one [7]. The cali-
bration slope is the slope from a logistic regression model
when the binary outcome is regressed on the estimated
linear predictor. The predicted probabilities are too low if
the calibration intercept is greater than zero and are too
high if the calibration intercept is less than zero. A calibra-
tion slope smaller than one indicates that the range of
observed probabilities is smaller than the range of predicted
probabilities [1,11].2.4. Statistical methods for assessing geographic and
temporal validity
The methods for assessing geographic and temporal val-
idity are summarized in Table 1.Table 1. Methods for assessing geographical and temporal model performan
Method
Methods that ignore temporal and geographic variation
Apparent performance Model performan
is made for th
validation.
Optimism-corrected performance Model is derived
estimate of mo
of bootstrap sa
Geographic transportability
Internaleexternal: Leave-one-hospital-out (pooled) Data from one ho
remaining hosp
to obtain pred
repeated so th
performance is
for each subjec
sample.
Internaleexternal: Leave-one-hospital-out
(meta-analysis)
As for internalee
we combine th
effects meta-a
Temporal transportability (model estimated in phase 1 and applied in phas
Fixed-effects regression model Model contains fi
models describ
Mixed-effects regression model Model contains h
Model is deriv
Case-mix adjusted performance Model is develop
probability of t
subject in phas
occurrence of
1,000 times t
Simultaneous geographic and temporal portability
Leave-one-hospital-out temporally (meta-analysis) Data from one ho
remaining hosp
from phase 2.
validation. The
random-effects
Leave-one-hospital-out temporally (pooled) Data from one ho
remaining hos
from phase 2.
validation. The
all hospitals a2.4.1. Model reproducibility: bootstrap estimates of
optimism-corrected performance
Apparent performance refers to the performance of the
model in the sample in which the model was developed.
The apparent estimate of model performance tends to be
optimistic because the model is derived in the same sample
in which its performance is being assessed. We may use
bootstrapping to adjust for this optimism [7] (Section 1 of
the Online Appendix). Bootstrap-corrected estimates of
performance assess the internal validity of the estimated
prediction model (or the reproducibility of the model
[3,4]). This denotes the expected performance of the model
if it were to be applied to new patients, from the same pop-
ulation as those used for model derivation. Alternative
methods exist to assess model reproducibility. These
include split-sample assessment and ‘‘leave-one-out’’ ap-
proaches [12,13]. We did not consider these methods as
previous studies that have found them to be inefficient
[14,15] or result in an underestimation of the c-statistic
when the number of events per variable was low [16].ce
Description
ce is assessed in the sample in which it was developed. No adjustment
e model being optimized to fit in the sample used for derivation and
in a bootstrap sample and applied to the overall sample to provide an
del optimism. The average optimism is computed over a large number
mples and is subtracted from the estimate of apparent performance.
spital are withheld and the model is derived using data from the
itals. The model is then applied to subjects from the withheld hospital
icted probabilities for each of the withheld subjects. This process is
at each hospital is excluded once from the derivation sample. Model
then determined in the pooled sample consisting of the predictions
t when that subject’s hospital was excluded from the model derivation
xternal, but rather than estimating performance on the pooled sample,
e hospital-specific estimates of model performance using a random-
nalysis.
e 2)
xed intercept and fixed effects for all covariates (similar to all the
ed previously). Model is derived in phase 1 and validated in phase 2.
ospital-specific random intercepts and fixed effects for all covariates.
ed in phase 1 and validated in phase 2.
ed in phase 1 and applied to subjects in phase 2. Using the predicted
he occurrence of the outcome, outcomes are simulated for each
e 2. Using the simulated outcome and the predicted probability of the
the outcome, model performance is assessed. This process is repeated
o obtain a stable estimate of model performance.
spital are withheld. The model is derived using phase 1 data from the
itals. The model is then validated in the excluded hospital using data
Process is repeated so that each hospital is used once for model
hospital-specific estimates of performance are then pooled using a
meta-analysis.
spital are withheld. The model is derived using phase 1 data from the
pitals. The model is then applied to the excluded hospital using data
Process is repeated so that each hospital is used once for model
estimated probability of the outcome is pooled across all patients at
nd the c-statistic is calculated.
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The following model was fit: logitðpijÞ5a0 þ Xijb, where
Xij denotes a vector containing the predictor variables, b de-
notes the vector of regression coefficients, and a0 denotes
the intercept, where the subscript ‘‘ij’’ denotes the ith patient
admitted to the jth hospital. Using the coefficients estimated
in the first phase of the sample, predicted probabilities of the
occurrence of the outcomewere then obtained for each subject
in the second phase of the sample. Both the discrimination and
calibration of the model estimated in the first phase of data
were assessed using the subjects from the second phase of
the study. As noted previously, the inclusion and exclusion
criteria differed slightly between the two phases of the study.
Although these methods were primarily intended to assess
the temporal portability of the model, they also reflect spec-
trum transportability.
We further examined whether incorporating hospital-
specific random effects in the prediction model estimated
in the first phase of the study improved its temporal porta-
bility. The prediction model described previously was
modified to include hospital-specific random effects when
fit in the first phase of the study: logitðpijÞ5a0j þ Xijb,
where a0j|Nða0; s2Þ.
2.4.3. Assessing geographic portability of the model
Within each of the two phases of the study, we exam-
ined the degree to which model performance varied across
hospitals. One hospital was excluded from the analytic
sample. The prediction model was estimated in the re-
maining hospitals. This process was repeated so that each
hospital was excluded once. We considered two different
methods for assessing geographic portability. The first,
referred to as ‘‘leave-one-hospital-out (pooled),’’ deter-
mined the predicted probability of the occurrence of the
outcome for each patient in the excluded hospital using
the model fit in the remaining hospitals. The predicted
probabilities for all patients at all hospitals were pooled,
and the performance of the prediction model was as-
sessed. This approach was used for both model discrimi-
nation and calibration. This approach can be seen as a
form of cross-validation, in which the strata consist of in-
dividual centers [17].
The second approach, referred to as ‘‘leave-one-hospi-
tal-out (meta-analysis),’’ is based on work by van Klave-
ren et al. [18] (Section 2 of the Online Appendix).
Hospital-specific measures of model performance were
obtained at each excluded hospital when the model was
fit using the sample of all of the other remaining hospi-
tals. Random-effects meta-analyses methods were used
to combine the individual hospital-specific estimates of
model performance. Pooled estimates of discrimination
and calibration were obtained as well as estimates of het-
erogeneity of the between-hospital variance (t2). It has
been suggested that I2 values of 25%, 50%, and 75%
can be considered to denote low, moderate, and high het-
erogeneity for treatment effect estimates [19]. We followthis classification in our study. Furthermore, prediction
intervals were calculated for the expected performance
of the clinical prediction model in centers that did not
contribute to their development.
These twomodels differ only in that the former pools all of
the patient-specific predicted probabilities and then computes
an overall measure of model performance, whereas the latter
pools hospital-specific estimates of model performance.2.4.4. Simultaneous geographic and temporal
transportability
We examined a ‘‘leave-one-hospital-out’’ approach to
examine geographic and temporal portability. One hospital
was selected from the set of 90 hospitals. The model was
estimated using patients admitted during phase 1 to the re-
maining 89 hospitals. The estimated prediction model was
then applied to patients admitted during phase 2 to the
selected hospital. When using the ‘‘leave-one-hospital-out
(meta-analysis)’’ approach, the c-statistic of the model,
when applied to patients from this single hospital in phase
2 was then determined. This process was repeated 90 times,
allowing each hospital to serve as the validation sample
once. The 90 estimates of the c-statistic were then pooled
using a random-effects meta-analysis, as described previ-
ously. In contrast, when using a ‘‘leave-one-hospital-out
(pooled)’’ approach, the predicted probabilities obtained
at each of the 90 hospitals (obtained when that hospital
was used as the validation sample) were pooled to provide
a single c-statistic.2.4.5. Effects of changes in case-mix on temporal vari-
ation in model performance
We examined whether changes in case-mix between
the two phases of the study had an effect on the temporal
validity of the prediction model [4]. First, the two phases
of the study were pooled and an indicator variable denot-
ing temporal period was regressed on the 11 variables in
the clinical prediction model and a binary variable denot-
ing 1-year mortality. The c-statistic of this model was
used as a measure of the degree to which the case-mix
of patients differed between the two study periods,
also referred to as a membership model [4]. Second,
we computed the linear predictor of the original
EFFECT-HF model estimated in the first phase of the
study and when applied to patients in the second
phase. Both the standard deviation and the mean of the
linear predictor were determined in each of the two
phases. Increased variability of the linear predictor de-
notes increased heterogeneity of case-mix. As heteroge-
neity increases, the expected discriminative ability of a
model increases [20].
In addition, we estimated the case-mix corrected c-sta-
tistic of the model developed in the first phase of the study,
when applied to the second phase of the study [21] (Section
3 of the Online Appendix).
Table 2. Estimated c-statistics obtained using different approaches
Method Phase 1 Phase 2
Reproducibility (performance in different patients from the same population)
Apparent performance 0.747 0.747
Optimism-corrected performance 0.745 0.745
Leave-one-hospital-out (pooled) 0.745 0.745
Leave-one-hospital-out (meta-analysis of model performance) 0.752 0.754
Temporal transportability (estimate in phase 1 and apply in phase 2)
No hospital-specific random effects (model contained a fixed intercept and fixed effects for the predictor variables) 0.745
With hospital-specific random effects (model contained hospital-specific intercepts and fixed effects for the
predictor variables)
0.745
Case-mix adjusted performance 0.746
Simultaneous geographic and temporal transportability
Model estimated in 89 hospitals in phase 1 and then applied to the excluded hospital in phase 2 (meta-analytic
pooling of performance estimates) (‘‘leave-one-hospital-out [meta-analysis]’’)
0.753
Model estimated in 89 hospitals in phase 1 and then applied to the excluded hospital in phase 2
(‘‘leave-one-hospital-out [pooled]’’)
0.745
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3.1. Reproducibility
The apparent c-statistic of the EFFECT-HF model was
0.747 in each of the two phases (Table 2). Bootstrap valida-
tion showed very little optimism in the apparent estimates
of performance (decrease by 0.002 to 0.745 in each of
the two samples).3.2. Geographic transportability
When using the ‘‘leave-one-hospital-out (pooled)’’
approach, the estimate of the c-statistic of the EFFECT-
HF model was the same as the bootstrap-corrected
estimates of the c-statistics observed previously. The
random-effects meta-analysis estimates of the mean
within-hospital c-statistics were slightly higher: 0.752
(95% CI 0.735e0.769) and 0.754 (95% CI
0.739e0.769) in the phase 1 and phase 2 samples, respec-
tively. The 95% prediction intervals were wide: (0.644,
0.859) and (0.689, 0.819), respectively. These denote
the intervals within which the true hospital-specific c-sta-
tistic for a new hospital is likely to lie. The width of these
prediction intervals reflects both the degree of between-
hospital heterogeneity in the hospital-specific c-statistics
(i.e., t2) and the standard deviation of the mean (which
is influenced by the size of the overall sample). The
values of t (which are estimates of the between-hospital
standard deviation of the hospital-specific performance)
in the two phases were 0.054 and 0.032, whereas the
values of I2 (which measures the degree of heterogeneity
in the hospital-specific measures of performance) in the
two phases were 48.5% and 23.9%. Thus, there was
moderately greater heterogeneity in the hospital-specific
c-statistics in the earlier time period compared to the later
time period (Fig. 1).
The overall calibration was nearly perfect using the
‘‘leave-one-hospital-out (pooled)’’ approach (Fig. 2). The
model displayed very good calibration in each of the twophases of the study, with some minor suggestion of under-
prediction in those patients with the lowest predicted prob-
ability of mortality. The random-effects meta-analysis
estimates of the hospital-specific calibration intercepts for
the EFFECT-HF model in the phase 1 and phase 2 samples
were 0.011 (95% CI 0.053, 0.075) and 0.016 (95% CI
0.059, 0.091), respectively. The 95% prediction intervals
were (0.317, 0.340) and (0.419, 0.451), respectively.
The I2 statistics in the two phases were 28.5% and
40.1%. Thus, there was low to modest heterogeneity in
the hospital-specific mortality. The random-effects meta-
analysis estimates of the hospital-specific calibration slopes
for the EFFECT-HF model in the phase 1 and phase 2 sam-
ples were 0.968 (95% CI 0.896, 1.040) and 0.964 (95% CI
0.892, 1.036), respectively. The 95% prediction intervals
were (0.643, 1.292) and (0.702, 1.225), with I2 equal to
21.7% and 14.3%, respectively. Thus, there was lower het-
erogeneity in the hospital-specific calibration slopes
(Fig. 3) than in the hospital-specific c-statistics. Thus, there
was no clear evidence of overfitting or different overall pre-
dictor effects when applying the prediction model to pa-
tients at different hospital within the same temporal period.3.3. Temporal transportability
When the EFFECT-HF model was estimated in the first
phase and then applied to the second phase, the estimated
c-statistic in the second phase was 0.745. When the model
was modified to incorporate hospital-specific random ef-
fects, the variance of the random intercepts was 0.02635
(resulting in a residual intraclass correlation coefficient of
0.008 [22]), and the resultant c-statistic remained un-
changed at 0.745 (hospital-specific random effects were
incorporated into the linear predictor when making
predictions).
Calibration for phase 2 showed a slope close to 1 (0.984,
95% CI 0.923, 1.046), and an intercept of 0.121 (95% CI
0.175, 0.067). Results were very similar with random
effects (0.979 and 0.115, respectively). Thus, the
Fig. 1. Random-effects meta-analyses of hospital-specific c-statistics.
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bration intercept !0). Overall calibration plots are
described in Fig. 4.
The c-statistic of the model for predicting study phase
was 0.580, suggesting similarity in case-mix between phase
1 and phase 2. The means of the linear predictors and the
standard deviations of the linear predictors were also very
similar. Indeed, the case-mix corrected c-statistic of the
model developed in phase 1 when applied to phase 2 was
0.746. This differed negligibly from the c-statistic of
0.745 that was obtained when the EFFECT-HF model
was developed in the phase 1 sample and applied to the
phase 2 sample.
3.4. Simultaneous geographic and temporal
transportability
When using the ‘‘leave-one-hospital-out (pooled)’’
approach, the estimated c-statistic was 0.745. When using
the ‘‘leave-one-hospital-out (meta-analysis)’’ approach,
the mean hospital-specific c-statistic from the random-
effects meta-analysis was 0.753, whereas the estimate of
t was 0.028. The value of the I2 statistic was 20.6%, with
95% prediction interval (0.693, 0.812).4. Discussion
We illustrated different strategies for assessing the
geographic and temporal performance of a clinical predic-
tion model for mortality in patients with heart failure. We
started with conventional strategies such as bootstrapping
and leave-one-hospital-out. When using leave-one-
hospital-out approaches, we considered a pooled approach
in which predicted probabilities were pooled, as well as
novel approaches based on random-effects pooling of
hospital-specific estimates of model performance. All stra-
tegies showed similar overall performance, but small-to-
moderate variation in performance by hospital (Table 2).
In Fig. 5, we summarize graphically some recommenda-
tions for assessing geographic and temporal portability of
clinical prediction models based on our reported analyses.
Bootstrap-based methods for optimism correction allow
one to assess model reproducibility: how well the model
will perform in different patients from the same population
in which the model was developed [14,15]. Frequently, re-
searchers do not have access to subjects from other centers
or different time periods with which to externally validate
the derived model. Thus, at the first stage of model devel-
opment and validation, the estimate of model
Fig. 2. Calibration in EFFECT samples (leave-one-hospital-out approach). EFFECT, The Enhanced Feedback for Effective Cardiac Treatment.
82 P.C. Austin et al. / Journal of Clinical Epidemiology 79 (2016) 76e85reproducibility often serves as the best initial estimate of
how well the model will perform in subsequent subjects
and in subjects from different centers and regions [3].
The apparent performance was very similar to the
bootstrap-corrected for optimism estimate of performance,
which is explained by the large sample size available in
each of the two phases in the present study. More optimism
is to be expected when smaller sample sizes are used for
model derivation [14].
A leave-one-hospital-out approach was very useful to
examine geographic transportability. The pooled estimates
of the model c-statistic were very similar to those ob-
tained using bootstrap correction for model optimism.
This finding may be unsurprising, as both approaches
can be seen as different forms of internal validation, with
the former being a form of cross-validation. We note that
as the number of centers that are included in model devel-
opment increases, the pooled performance of the model in
a different set of centers will likely be comparable to the
performance of the model in the full derivation sample.
Geographical transportability is more likely to be poor
when the model was developed at a single center than
when it was developed using subjects from a large number
of centers.
We emphasize that developing a model in a large set of
centers does not guarantee that there will be negligible vari-
ation in the hospital-specific performance of the model
when applied to a new set of centers. This variation can
be studied using random-effects meta-analytic methods[23]. Such a meta-analytic approach produces an estimate
of the pooled hospital-specific c-statistic but also of the
variance of the hospital-specific c-statistics. One could
argue that geographic transportability is primarily indicated
by this variation of performance across the centers, as this
denotes the degree to which model performance can be ex-
pected to vary across centers (heterogeneity). We found that
there was more between-centre heterogeneity in perfor-
mance in phase 1 than in phase 2, and more in c-statistics
than in calibration slopes. The latter may reflect that the
c-statistic depends both on case-mix differences and differ-
ences in model fit to specific centers [4,20,21].
When we simultaneously examined temporal and
geographic transportability, the overall c-statistic was iden-
tical to the assessment of the temporal transportability.
Similarly, this estimate was equal to that obtained in each
of the two phases of the study when using a leave-one-
hospital-out approach, as described previously.
When comparing methods for assessing the temporal
transportability of the prediction model, identical estimates
of the overall c-statistic were obtained regardless of
whether one included hospital-specific random effects in
the clinical prediction model (with a residual intraclass cor-
relation coefficient of 0.008, the between-centre variation in
mortality was low). The ability to omit hospital-specific
random effects is advantageous because these will be of
use only when the model is applied to patients admitted
to the same hospitals as those in which the model was
developed.
Fig. 3. Meta-analyses of calibration intercepts and slopes using a leave-one-hospital-out approach.
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conduct a true assessment of external validation. Many of
the analyses that we described would constitute ‘‘internal-
external validation,’’ whereas our assessment of model
reproducibility would constitute internal validation [24].
The highest standard for external validation would entail
validating the derived model in patients from a different
temporal period, from a different geographic period and
by different investigators from those who developed the
original model. Some of our analyses fulfilled the first
two criteria. However, the final criterion was not satisfied,
as the same study investigators were responsible for the
study design and data collection in both phases of the study.
The strength of arguments for geographic and temporal
transportability in our setting would depend on the differ-
ences between the hospitals selected for model derivation
and those selected for model validation and the temporal
difference between the two time periods.
In the present study, we only considered the inclusion
of patient-level characteristics in the clinical prediction
model. This reflects the typical development of clinical
prediction models, in which hospital or system character-
istics are excluded from the model. It is possible thatinclusion of hospital characteristics (e.g., hospital volume
of the condition in question, academic affiliation, staff
training, etc.) can improve the performance of the model.
Furthermore, the inclusion of such characteristics may
result in models with improved geographic transport-
ability, if the distribution of hospital characteristics differs
between the centers that were used for model develop-
ment and the centers in which the model will ultimately
be applied (the variance of the random effects can give
some indication of the potential for subsequent improve-
ments). However, the inclusion of such characteristics
could result in an unwarranted extrapolation if the hospi-
tals to which the model was applied differed substantially
from those used for derivation (i.e., if the model was
developed at low-volume centers and then applied at
high-volume centers).
In summary, we illustrated the application of a set of an-
alytic methods for assessing the reproducibility, geographic
transportability, and temporal transportability of clinical
prediction models. We focused here on the traditional
concept of validity, that is, assessing performance, specif-
ically calibration and discrimination, in subjects not
considered at model development. An alternative
Fig. 4. Temporal calibration in phase 2 sample with and without random effects.
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within the full data set [24]. We expand on this perspective
in a companion article [25]. Understanding the purpose of
each validation approach, its strengths and limitations, as• Use bootstrap-correction 
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reproducibility.
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and then estimate performance in
the second time period (temporal 
transportability).
Fig. 5. Recommendations for validatwell as its interpretation, will permit investigators to better
assess the performance of clinical prediction models as
well as to assess the quality of validations presented in
the literature.• Use random effects meta-analysis 
of leave-one-out estimates to 
assess geographic transportability.
Also pool estimated predictions to 
generate an overall pooled 
estimate of model performance.
• Use leave-one-hospital-out approach to 
select one hospital for performance 
estimation in later time phase. Use 
remaining hospitals for model 
development in first phase. Use random 
effects meta-analysis to pool estimates of 
performance. Also pool estimated 
predictions to generate an overall pooled 
estimate of model performance.
Multicenter data available
ing clinical prediction models.
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Supplementary data related to this article can be found at
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